AML Clinical Trial
Official title:
A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs—cytarabine and etoposide. We want to find out what effects, good and /or bad, this combination of drugs has on leukemia. Plerixafor is a drug that blocks a receptor on the leukemia cell, which prevents it from staying in the bone marrow where it can be resistant to chemotherapy. Plerixafor is FDA approved for mobilizing stem cells from the bone marrow in preparation for an autologous stem cell transplant. Cytarabine and etoposide have been used as part of standard chemotherapy for ALL and AML. However, the use of plerixafor with cytarabine and etoposide in pediatric patients with relapsed or refractory ALL, AML and MDS is considered experimental.
Approximately 500 children are diagnosed with AML every year, of whom around 60% are cured
with current regimens based on anthracyclines and high dose cytarabine with or without stem
cell transplant (SCT). Among the remaining 40% who are refractory or who relapse, outcome is
dismal. Additionally, 20-30% of patients with childhood ALL relapse or become refractory to
frontline therapies. The prognosis is poor in this patient population, particularly in
patients with second or subsequent relapse and those who relapse following SCT. These
patients present myriad challenges, as they usually have received a high cumulative
anthracycline dose, and in the case of SCT, may have had significant organ toxicities and/or
total body irradiation (TBI). Therefore, new therapeutic strategies need to be identified to
enhance possible improved outcomes.
Recently, scientists have described a resistant, quiescent population of leukemia cells that
have limitless self-renewal potential. The identification of these "leukemia stem cells"
(LSCs) provides an additional strategy in treating and preventing relapsed/refractory acute
leukemia. One mechanism for resistance to treatment is the protection afforded LSCs via the
interaction between stem cell derived growth factor (CXCL-12/SDF-1α) and its receptor, CXCR4.
These interactions are implicated in chemotaxis, homing, and survival/apoptosis of
hematopoietic stem cells and progenitor cells. All AML and ALL cells express CXCR4 and
SDF-1α. AMD3100 (plerixafor, MOBOZIL®) is a bicyclam that blocks CXCL-12 binding to and
signaling through CXCR4, thus disrupting tumor-stroma interactions and mobilizing leukemia
cells from their protective stromal environment. Plerixafor is currently FDA approved for use
in stem cell mobilization for autologous transplantation in hematologic malignancies.
Clinical trials in adult patients with relapsed AML have demonstrated promising results when
combining plerixafor with cytotoxic chemotherapy.
This Phase I clinical trial will be the first to test the concept of a "chemosensitization"
approach in children using Plerixafor. Patients aged 3 to 30 with relapsed/refractory AML,
ALL or MDS will receive Plerixafor followed 4 hours later with combination chemotherapy
consisting of etoposide and cytarabine daily for five days. We will determine the safety and
tolerability of Plerixafor in combination with cytarabine and etoposide in pediatric and
young adults with relapsed/refractory acute leukemias. The secondary objectives of this study
will quantify the peripheral blood mobilization of blasts in response to Plerixafor using
flow cytometry, measure initial CXCR4 expression on leukemic blasts and correlate with
response, and determine the change in CXCR4 expression after protocol therapy. Finally, we
will determine the pharmacokinetics of Plerixafor when administered with cytotoxic
chemotherapy in this patient population.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03118466 -
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
Withdrawn |
NCT03444649 -
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
|
Phase 1 | |
Withdrawn |
NCT02905994 -
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT02261779 -
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
|
Phase 1/Phase 2 | |
Completed |
NCT00246649 -
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Terminated |
NCT01570465 -
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
|
||
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 | |
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Completed |
NCT02575963 -
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00780598 -
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
|
Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Completed |
NCT00542971 -
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
|
Phase 1/Phase 2 | |
Completed |
NCT00589082 -
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
|
Phase 3 |